关键信息
-
基因名
FLCN
- 应用
-
别名
BHD; FLCL; BHD skin lesion fibrofolliculoma protein; Birt-Hogg-Dube syndrome protein
-
种属
Human
-
表达系统
E. coli
-
标签
Two N- s, His- & SUMO-
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q8NFG4
-
表达区间
Arg341~Asn579
-
分子量
41kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
FLCN (Folliculin) is a tumor suppressor protein encoded by the FLCN gene, which has been linked to the development of Birt-Hogg-Dubé syndrome (BHDS), a genetic disorder characterized by skin tumors, lung cysts, and an increased risk of renal cancer. Recent research has highlighted the critical role of FLCN in cellular processes such as energy metabolism, cell proliferation, and DNA damage response. The protein is part of the mTOR signaling pathway, which is essential for cellular growth and homeostasis. Studies have shown that mutations or loss of FLCN function can lead to dysregulation of these pathways, contributing to tumorigenesis. To better understand FLCN's biological functions and mechanisms of action, researchers have focused on the expression and purification of recombinant FLCN protein. This enables the exploration of its structural properties, interactions with other molecular partners, and regulatory roles within the cell. By studying FLCN in a controlled environment, scientists aim to uncover the molecular basis of BHDS and other related disorders, providing insights that could lead to targeted therapies and improved clinical outcomes. The elucidation of FLCN's function is crucial not just for understanding kidney cancer and BHDS, but also for broader applications in cancer biology and treatment strategies.
